期刊
CURRENT MEDICAL SCIENCE
卷 41, 期 3, 页码 465-473出版社
SPRINGER
DOI: 10.1007/s11596-021-2394-2
关键词
diffuse large B-cell lymphoma; intermediate; high risk; autologous hematopoietic stem cell transplantation; frontline therapy
资金
- National Natural Science Foundation of China [82070208]
- Technique Innovation and Applied Program of Chongqing [cstc2019jscx-msxmX0187]
- Natural Science Key Foundation of Chongqing [cstc2019jcyj-zdxmX0023]
- Science and Technology Innovation Promotion Project of Army Medical University [2019XLC3020]
- Translational Research Program of National Clinical Research Center for Hematologic Diseases [2020ZKZC02, 2021WWB05]
The study demonstrates that frontline auto-HSCT can improve the prognosis of intermediate/high-risk DLBCL patients, resulting in higher overall survival and progression-free survival rates.
The role of autologous hematopoietic stem cell transplantation (auto-HSCT) following high-dose chemotherapy has been validated and accepted as a standard treatment for patients with relapsed diffuse large B-cell lymphoma (DLBCL). However, its clinical efficacy as frontline therapy remains to be elucidated. This study aimed to examine the feasibility of frontline auto-HSCT for newly diagnosed intermediate/high-risk DLBCL patients. We retrospectively reviewed the data of 223 patients treated with frontline auto-HSCT or chemotherapy alone (year 2008-2014) from four hospitals. The median follow-up time was 29.4 months. Between the two treatment arms among the intermediate/high-risk DLBCL patients, the 3-year overall survival (OS) and progression-free survival (PFS) rates of patients given frontline auto-HSCT were 87.6% and 81.9%, respectively, and the chemotherapy-alone group showed 3-year OS and PFS rates of 64.9% and 59.59%, respectively. Compared with the chemotherapy-alone group, the frontline auto-HSCT could eliminate the adverse impact of non-germinal center B-cell (GCB) type. In addition, in the frontline auto-HSCT group, patients who achieved complete response (CR) at auto-HSCT had a longer survival time than those who did not achieve CR. Our results suggested that frontline auto-HSCT could improve the prognosis of intermediate/high-risk DLBCL patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据